BCM
DMK

BlueCrest Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

BlueCrest Capital Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-696
Closed -$103K – 1119
2019
Q1 		$103K Buy
+696
New +$135K ﹤0.01% 1076
2018
Q2 		– Sell
-294
Closed -$72K – 1907
2018
Q1 		$72K Buy
+294
New +$77.2K ﹤0.01% 1399

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's DMK Position: Q2 2019 in Review

BlueCrest Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2019, closing a stake of 696 shares — an estimated $103K sold.

BlueCrest Capital Management first reported a position in DMK in Q1 2018 and held it in 2 quarters. The position peaked at $103K in Q1 2019. 51 funds tracked by Wall St. Rank hold DMK as of Q2 2019.

  • BlueCrest Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 696 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2019, an estimated $103K.
  • BlueCrest Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $103K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.